ABCG2 Antibody - #AF5177

(17)   (18)  
Product: ABCG2 Antibody
Catalog: AF5177
Description: Rabbit polyclonal antibody to ABCG2
Application: WB IHC IF/ICC
Cited expt.: WB, IHC
Reactivity: Human, Mouse, Rat
Prediction: Rabbit
Mol.Wt.: 72 kDa; 72kD(Calculated).
Uniprot: Q9UNQ0
RRID: AB_2837663

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
IF/ICC 1:100-1:500, WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Rabbit(89%)
Clonality:
Polyclonal
Specificity:
ABCG2 Antibody detects endogenous levels of total ABCG2.
RRID:
AB_2837663
Cite Format: Affinity Biosciences Cat# AF5177, RRID:AB_2837663.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ABC transporter; ABC15; ABCG 2; ABCG2; ABCG2_HUMAN; ABCP; ATP binding cassette sub family G (WHITE) member 2; ATP binding cassette transporter G2; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; BMDP; Breast cancer resistance protein; CD338; CDw338; CDw338 antigen; EST157481; GOUT1; MGC102821; Mitoxantrone resistance associated protein; Mitoxantrone resistance-associated protein; MRX; Multi drug resistance efflux transport ATP binding cassette sub family G (WHITE) member 2; MXR; MXR1; Placenta specific ATP binding cassette transporter; Placenta specific MDR protein; Placenta-specific ATP-binding cassette transporter; UAQTL1;

Immunogens

Immunogen:

A synthesized peptide derived from human ABCG2, corresponding to a region within the internal amino acids.

Uniprot:

Q9UNQ0(ABCG2_HUMAN) >>Visit HPA database.

Gene(ID):
ABCG2(9429)
Expression:
Q9UNQ0 ABCG2_HUMAN:

Highly expressed in placenta (PubMed:9850061). Low expression in small intestine, liver and colon (PubMed:9861027). Expressed in brain (at protein level) (PubMed:12958161).

Description:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain.
Sequence:
MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVEKEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCNSGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGTQFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIFSIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIINGDSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKKITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDSTGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLPMRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLLMTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGNNPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Rabbit
89
Bovine
78
Sheep
78
Pig
75
Horse
67
Xenopus
56
Dog
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Broad substrate specificity ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes a wide variety of physiological compounds, dietary toxins and xenobiotics from cells. Involved in porphyrin homeostasis, mediating the export of protoporphyrin IX (PPIX) from both mitochondria to cytosol and cytosol to extracellular space, it also functions in the cellular export of heme. Also mediates the efflux of sphingosine-1-P from cells. Acts as a urate exporter functioning in both renal and extrarenal urate excretion. In kidney, it also functions as a physiological exporter of the uremic toxin indoxyl sulfate (By similarity). Also involved in the excretion of steroids like estrone 3-sulfate/E1S, 3beta-sulfooxy-androst-5-en-17-one/DHEAS, and other sulfate conjugates. Mediates the secretion of the riboflavin and biotin vitamins into milk (By similarity). Extrudes pheophorbide a, a phototoxic porphyrin catabolite of chlorophyll, reducing its bioavailability (By similarity). Plays an important role in the exclusion of xenobiotics from the brain (Probable). It confers to cells a resistance to multiple drugs and other xenobiotics including mitoxantrone, pheophorbide, camptothecin, methotrexate, azidothymidine, and the anthracyclines daunorubicin and doxorubicin, through the control of their efflux. In placenta, it limits the penetration of drugs from the maternal plasma into the fetus (By similarity). May play a role in early stem cell self-renewal by blocking differentiation (By similarity).

PTMs:

N-glycosylated. Glycosylation-deficient ABCG2 is normally expressed and functional.

Phosphorylated. Phosphorylation at Thr-362 by PIM1 is induced by drugs like mitoxantrone and is associated with cells increased drug resistance. It regulates the localization to the plasma membrane, the homooligomerization and therefore, the activity of the transporter.

Subcellular Location:

Cell membrane>Multi-pass membrane protein. Apical cell membrane>Multi-pass membrane protein. Mitochondrion membrane>Multi-pass membrane protein.
Note: Enriched in membrane lipid rafts.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Highly expressed in placenta. Low expression in small intestine, liver and colon. Expressed in brain (at protein level).

Family&Domains:

The extracellular loop 3 (ECL3) is involved in binding porphyrins and transfer them to other carriers, probably albumin.

Belongs to the ABC transporter superfamily. ABCG family. Eye pigment precursor importer (TC 3.A.1.204) subfamily.

Research Fields

· Environmental Information Processing > Membrane transport > ABC transporters.

· Human Diseases > Drug resistance: Antineoplastic > Antifolate resistance.

References

1). Target deubiquitinase OTUB1 as a therapeatic strategy for BLCA via β-catenin/necroptosis signal pathway. International journal of biological sciences, 2024 (PubMed: 39113709) [IF=8.2]

Application: WB    Species: Mouse    Sample: BLCA cells

Figure 7. OTUB1 is involved in cisplatin resistance of BLCA through β-catenin stabilization. A. Cell survival assay was determined in T24 control cell and T24 cisplatin-resistance cell. B. The changes in cell morphology between the T24 control cell and the T24 cisplatin-resistance cell. C. Relative expression of several chemoresistance markers (including MDR1, BCRP and YB-1) in T24 control cell and T24 cisplatin-resistance cell with or without cisplatin treatment. D. Relative expression of OTUB1 in T24 control cell and T24 cisplatin-resistance cell with or without cisplatin treatment. E. Relative expression of OTUB1, necroptosis-related markers (such as RIPK3, MLKL and P-MLKL), β-catenin and downstream proteins (including AXIN-2, C-myc, cyclin D1 and TCF1) in T24 cisplatin-resistance cells treated with gradient cisplatin concentration. F. Immunoprecipitation assay showed the relationship between OTUB1 and β-catenin in T24 cisplatin-resistance cells. G. Immunoprecipitation assay showed that gradient cisplatin concentration promotes the interaction between OTUB1 and β-catenin, and restrains the ubiquitination of β-catenin. H. Relative expression of OTUB1, necroptosis-related markers (such as RIPK3, MLKL and P-MLKL), β-catenin and downstream targets following elevated OTUB1, β-catenin with or without XAV-939 treatment in T24 cisplatin-resistance cell (control, OTUB1, OTUB1/XAV-939, β-catenin). I. Cell survival assay was determined in T24 cisplatin-resistance cells following overexpressed OTUB1 with or without 10uM XAV-939 (or knockdown OTUB1 with or without overexpressed β-catenin). J. Knockdown OTUB1 restrains the growth in T24 cisplatin-resistance mice bladder tumor in vivo.
2). Tumor-associated macrophages/C-X-C motif chemokine ligand 1 promotes breast cancer autophagy-mediated chemoresistance via IGF1R/STAT3/HMGB1 signaling. Cell death & disease, 2024 (PubMed: 39394189) [IF=8.1]

Application: WB    Species: Mouse    Sample: MDA-MB-231 cells

Fig. 1: TAMs enhanced breast cancer cell chemoresistance by activating autophagy. A Flow cytometry analysis confirmed the successful induction of M2-TAMs by staining with CD163 and F4/80. B Cell counting assay was performed in MDA-MB-231 and MCF-7 cells to determine the effect of TAMs-CM on the cell growth response to paclitaxel (50 nM) with or without autophagic inhibitor 3-Ma (10 mM) after 48 h treatment. C Western blotting assay was conducted to evaluate the effects of TAMs-CM on expressions of ABCG2, SQSTM1/p62 and LC3 levels in MDA-MB-231 and MCF-7 cells. The autophagic activator rapamycin (RAPA, 10 nM) was used as a positive control. D Western blotting assay was conducted to evaluate the synergistic effects of TAMs-CM with autophagic inhibition by either 3-Ma administration or ATG5 knockdown on expressions of ABCG2, SQSTM1/p62 and LC3 levels. E The autophagic flux of MDA-MB-231 cells and MCF-7 cells was assessed through transfection with mRFP-GFP-LC3 lentiviral vectors after exposure to TAMs-CM, with or without autophagic inhibition by either 3-Ma administration or ATG5 knockdown. The autophagic activator RAPA (10 nM) was used as a positive control (n = 5, scale bars indicate 20 μm). F Transmission electron microscope detection demonstrated the presence of autolysosomes (red arrows) and autophagosomes (yellow arrows) in MDA-MB-231 and MCF-7 cells after the indicated treatments. Values are presented as Mean ± SD, n = 3 unless otherwise indicated, *P 
3). Aqueous extract of Phellinus igniarius ameliorates hyperuricemia and renal injury in adenine/potassium oxonate-treated mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024 (PubMed: 38879892) [IF=6.9]
4). Caffeic acid phenethyl ester alleviated hypouricemia in hyperuricemic mice through inhibiting XOD and up-regulating OAT3. PHYTOMEDICINE, 2022 (PubMed: 35714456) [IF=6.7]
5). Artemetin targets the ABCG2/RAB7A axis to inhibit mitochondrial dysfunction in asthma. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2025 (PubMed: 40088742) [IF=6.7]
6). Chinese Sumac (Rhus chinensis Mill.) Fruits Prevent Hyperuricemia and Uric Acid Nephropathy in Mice Fed a High-Purine Yeast Diet. Nutrients, 2024 (PubMed: 38257077) [IF=5.9]

Application: WB    Species: Mouse    Sample:

Figure 6 Effect of CE on the expression (A) and relative expressions (B) of several key proteins related to uric acid transport in the kidney, including ABCG2, URAT1, and SLC2A9 (n = 6/group). The relative expression level was quantified to 1 as the ratio of the blank group to β-actin as a standard for comparison. Different letters on the same bar graph indicate significant differences (p < 0.05). C, control group; M, model group; P, positive group (5 mg/kg b.w. of allopurinol). YL, CE low dose group (400 mg/kg b.w. of CE) and YH, CE high dose group (800 mg/kg b.w. of CE).
7). Piperine Improves Hyperuricemic Nephropathy by Inhibiting URAT1/GLUT9 and the AKT-mTOR Pathway. Journal of agricultural and food chemistry, 2024 (PubMed: 38498316) [IF=5.7]
8). Whey Protein Peptide Pro-Glu-Trp Ameliorates Hyperuricemia by Enhancing Intestinal Uric Acid Excretion, Modulating the Gut Microbiota, and Protecting the Intestinal Barrier in Rats. Journal of agricultural and food chemistry, 2024 (PubMed: 38240209) [IF=5.7]
9). MiR-21 modulates the polarization of M2 macrophages and increases the effects of M2 macrophages on promoting the chemoresistance of ovarian cancer. LIFE SCIENCES, 2020 (PubMed: 31837336) [IF=5.2]

Application: WB    Species: human    Sample: ovarian cancer cells

Figure 2. |Characterization of M0, M1 and M2 macrophages. M2 macrophages could promote the chemoresistance of ovarian cancer cells.(F) Western blotting was used to test the expression levels of cleaved caspase 3, ABCG2 and MDR1 in the ovarian cancer cells which co-cultured with M0 and M2 macrophages. U6 and GAPDH were used as the control. The columns showed as the mean ± SE of triplicate samples. *P < 0.05; **P < 0.01; ***P < 0.001.
10). Hypouricaemic and nephroprotective effects of Poria cocos in hyperuricemic mice by up-regulating ATP-binding cassette super-family G member 2. PHARMACEUTICAL BIOLOGY, 2021 (PubMed: 33651969) [IF=3.9]

Application: WB    Species: Mice    Sample: kidney tissues

Figure 4. Effects of PCE and PCW on renal ABCG2, OAT3, OAT1 and OCT2 protein expression detected by Western blot: immunoreactive bands (a) and densitometries (b,c,d and –e, expressed as mean ± SD; n n ¼ 3).  p < 0.05,  p < 0.01 versus the normal control; #p < 0.05, ##p < 0.01 versus the hyperuricemic control;  p < 0.01 versus the allopurinol control.
Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.